Suchergebnisse - "Xiang, Yufei"

PubPharm (115)

11

BROADLY NEUTRALIZING NANOBODIES FOR CORONAVIRUS AND USES THEREOF

enthalten in: Europäisches Patentamt | 2023

von SHI YI | XIANG YUFEI

12

Distribution of autoantibodies to insulinoma-associated antigen-2 and zinc transporter 8 in type 1 diabetes and latent autoimmune diabetes : A nationwide, multicentre, cross-sectional study

enthalten in: Diabetes/metabolism research and reviews | 2023

von Fan, W. | Nan, X. | Peng, Y. | +13

13

Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses

enthalten in: bioRxiv.org | 2022

von Nambulli, S. | Xiang, Y. | Tilston-Lunel, N. | +7

14

A robust and versatile nanobody platform for drug delivery

enthalten in: bioRxiv.org | 2022

von Shen, Z. | Xiang, Y. | Vegara, S. | +12

15

Reduced B cell antigenicity of Omicron lowers host serologic response

enthalten in: Cell reports | 2022

von Tubiana, J. | Xiang, Y. | Fan, L. | +4

UpdateOf: bioRxiv. 2022 Feb 15;:. - PMID 35194608

16

Pancreatic islet-specific engineered Tregs exhibit robust antigen-specific and bystander immune suppression in type 1 diabetes models

enthalten in: Science translational medicine | 2022

von Yang, S. | Singh, A. | Drow, T. | +15

CommentIn: Nat Rev Endocrinol. 2023 Jan;19(1):4. - PMID 36316390

17

Thyroid autoantibody distribution in patients with latent autoimmune diabetes in youth : a multicenter, national survey

enthalten in: Annals of translational medicine | 2022

von Nan, X. | Li, X. | Xiang, Y. | +10

18

Superimmunity by pan-sarbecovirus nanobodies

enthalten in: Cell reports | 2022

von Xiang, Y. | Huang, W. | Liu, H. | +9

19

The Magic of Linking Rings : Discovery of a Unique Photoinduced Fluorescent Protein Crosslink

enthalten in: Journal of the American Chemical Society | 2022

von Lu, M. | Toptygin, D. | Xiang, Y. | +6

20

Llamanade: an open-source computational pipeline for robust nanobody humanization

enthalten in: bioRxiv.org | 2022

von Sang, Z. | Xiang, Y. | Bahar, I. | +1